Update of the serotonergic hypothesis of obsessive compulsive disorder.
Zohar
J
J
Anxiety Clinic, Chaim Sheba Medical Center, Tel Hashomer, Israel.
Kindler
S
S
D004311:Double-Blind Method; D006801:Humans; D009771:Obsessive-Compulsive Disorder / Q000188:drug therapy / Q000503:physiopathology*; D010879:Piperazines / Q000009:adverse effects; D011719:Pyrazines / Q000627:therapeutic use; D016194:Receptors, N-Methyl-D-Aspartate / Q000037:antagonists & inhibitors; D012701:Serotonin / Q000502:physiology*; D012702:Serotonin Antagonists / Q000627:therapeutic use
D010879:Piperazines; D011719:Pyrazines; D016194:Receptors, N-Methyl-D-Aspartate; D012702:Serotonin Antagonists; D012701:Serotonin; C014896:6-chloro-2-(1-piperazinyl)pyrazine; C050592:3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid